Loading condition report…
Loading condition report…
Persistent and disabling ANXIETY.
Evidence at a glance
Open any number to go directly to the underlying records.
The report maps directly scoped documents, study registrations, formulations and exact source-reported evidence. Efficacy, treatment and safety conclusions remain unvalidated. Every item links back to preserved source material. Study registrations and dose records describe what researchers reported or planned; they are not treatment advice or proof that an intervention works.
Condition scope
Subtype counts can overlap because one article may discuss more than one condition.
Research map
These are document-level associations. The first group has study-registration or regulatory context; neither group proves efficacy or clinical use.
Social anxiety disorder · Generalized anxiety disorder · Panic disorder
registered studies · not a treatment claimGeneralized anxiety disorder · Social anxiety disorder
document association · not a treatment claimGeneralized anxiety disorder
How treatment was studied
Routes and dose values below describe registered or published research. They are not prescribing instructions.
What researchers planned or recorded in trial registrations.
No exact dose descriptions were present in this frozen report snapshot.
How the intervention was described as being given in registered studies.
Open a route to see its registrations. A study may appear under more than one route.
Source-backed observations from readable publications.
Systematic review: researchers use a documented method to find, select and assess all relevant studies for a specific question.
Meta-analysis: when the studies are sufficiently comparable, their numerical results are combined statistically.
These methods can provide a broader view than one study, but their reliability still depends on the quality and similarity of the included evidence. They do not automatically prove that a treatment works.
No publication-level dosing evidence is available in this frozen snapshot.
How the research was designed
These labels describe the registered study design—not whether the treatment worked. A study can use several methods, so categories may overlap. Protocol categories are deterministic title/type matches and use a multi-label taxonomy. Filters preserve every matching tag while each registration is shown once. Registration is not a result.
Showing 6 of 6 unique registrations. 7 pattern memberships are preserved as badges; counts may overlap.
Research frequency
Counts use the directly scoped, rights-cleared article snapshot. The current year is partial.
Registries
A registration describes the protocol. When posted, source-reported outcomes and safety are preserved on the local Study page.
Browse the complete filtered study catalog →
Showing 12 of 15 directly scoped registrations.
90 enrolled
Open study record27 enrolled
Open study record68 enrolled
Open study record42 enrolled
Open study record63 enrolled
Open study record50 enrolled
Open study record24 enrolled
Open study record0 enrolled
Open study record100 enrolled
Open study record50 enrolled
Open study record0 enrolled
Open study record60 enrolled
Open study recordSupporting evidence and regulatory context
Available items are locally preserved, frozen candidates. Funding and related research remain unavailable until a complete relevance-policy-v2 section is frozen; unavailable safety linkage is never presented as zero. Source metadata and safety reports are not efficacy or causality claims.
Frozen 14/09/2026 · 13,744 records · source sync still in progress
PUBLIC HEALTH RELEVANCE: Although people with cannabis dependence are highly vulnerable to anxiety disorders, and elevated anxiety is related to poorer cannabis dependence treatment outcomes, previous research has not examined how to effectively treat patients with co-occurring cannabis dependence and anxiety disorders. The goal of the current research is to develop and evaluate the feasibility of a specialized therapy for treating these persons. The overarching aim is to decrease cannabis use, cannabis-related problems and withdrawal symptoms, anxiety, and disability while simultaneously improving quality of life and examining possible mechanisms underlying treatment outcomes.
Cognitive behavioral therapy (CBT) is a first-line approach in the treatment of generalized anxiety disorder (GAD) and works to improve emotion regulation skills by targeting dysfunctional thoughts and behaviors with exposure and cognitive restructuring techniques. CBT is generally effective, but up to half of all patients do not show significant improvement or fail to sustain improvements over time. The goal of the current proposal is to investigate the cannabinoid system as a potential target for increasing efficacy and durability of CBT in treating GAD (e.g., shortening treatment while strengthening and prolonging gains).
Cannabis-based products are commonly used by the public to self-manage symptoms of anxiety; however, people are making decisions about what product to use and at what doses in the absence of scientific evidence. The proposed studies will be the first to examine the effects of different doses of cannabidiol (CBD) on biological and anxiety responses within a patient sample. Findings from these projects will inform whether, and at what dose, CBD is likely to reduce anxiety symptoms, thereby opening new horizons for establishing the potential therapeutic benefit of CBD for anxiety and stress-related conditions.
Project Narrative The common co-occurrence of anxiety disorders and substance use disorders is associated with poor outcomes, but access to evidence-based treatments that integrate behavioral approaches for both problems into one streamlined intervention is lacking. This is a two-phased project that aims to develop and preliminarily evaluate a digital therapy for comorbid anxiety and substance use disorders that is based on a model of integrated cognitive and behavioral principles that has been developed and evaluated by the Principal Investigator in prior research.
PROJECT NARRATIVE There remains a pressing need for novel treatments for social anxiety disorder, a common and impairing early onset condition with core symptoms of social and performance fears and avoidance that has demonstrated abnormalities in fear neurocircuitry. Cannabidiol (CBD) is a safe natural compound from the cannabis plant for which there exists strong preclinical and well-replicated human laboratory evidence for CBD’s acute anxiolytic effects, making it one of the most promising novel drug candidates for development for the treatment of anxiety, and social anxiety in particular. This proposal builds on promising preliminary scientific support for potential engagement with SAD-relevant behavioral, neural and clinical effects of CBD to establish a biological signature of CBD’s putative therapeutic effects in SAD and its link to core SAD symptoms, and to provide clinical effect sizes, safety, and feasibility data to guide a future definitive efficacy study to establish CBD as a novel evidence based treatment for SAD.
Although people with cannabis dependence are highly vulnerable to anxiety disorders, and elevated anxiety is related to poorer cannabis dependence treatment outcomes, previous research has not examined how to effectively treat patients with co-occurring cannabis dependence and anxiety disorders. The goal of the current research is to develop and evaluate the feasibility of a specialized therapy for treating these persons. The overarching aim is to decrease cannabis use, cannabis-related problems and withdrawal symptoms, anxiety, and disability while simultaneously improving quality of life and examining possible mechanisms underlying treatment outcomes.
Cognitive behavioral therapy (CBT) is a first-line approach in the treatment of generalized anxiety disorder (GAD) and works to improve emotion regulation skills by targeting dysfunctional thoughts and behaviors with exposure and cognitive restructuring techniques. CBT is generally effective, but up to half of all patients do not show significant improvement or fail to sustain improvements over time. The goal of the current proposal is to investigate the cannabinoid system as a potential target for increasing efficacy and durability of CBT in treating GAD (e.g., shortening treatment while strengthening and prolonging gains).
Cannabis-based products are commonly used by the public to self-manage symptoms of anxiety; however, people are making decisions about what product to use and at what doses in the absence of scientific evidence. The proposed studies will be the first to examine the effects of different doses of cannabidiol (CBD) on biological and anxiety responses within a patient sample. Findings from these projects will inform whether, and at what dose, CBD is likely to reduce anxiety symptoms, thereby opening new horizons for establishing the potential therapeutic benefit of CBD for anxiety and stress-related conditions.
Although people with cannabis dependence are highly vulnerable to anxiety disorders, and elevated anxiety is related to poorer cannabis dependence treatment outcomes, previous research has not examined how to effectively treat patients with co-occurring cannabis dependence and anxiety disorders. The goal of the current research is to develop and evaluate the feasibility of a specialized therapy for treating these persons. The overarching aim is to decrease cannabis use, cannabis-related problems and withdrawal symptoms, anxiety, and disability while simultaneously improving quality of life and examining possible mechanisms underlying treatment outcomes.
PROJECT NARRATIVE There remains a pressing need for novel treatments for social anxiety disorder, a common and impairing early onset condition with core symptoms of social and performance fears and avoidance that has demonstrated abnormalities in fear neurocircuitry. Cannabidiol (CBD) is a safe natural compound from the cannabis plant for which there exists strong preclinical and well-replicated human laboratory evidence for CBD’s acute anxiolytic effects, making it one of the most promising novel drug candidates for development for the treatment of anxiety, and social anxiety in particular. This proposal builds on promising preliminary scientific support for potential engagement with SAD-relevant behavioral, neural and clinical effects of CBD to establish a biological signature of CBD’s putative therapeutic effects in SAD and its link to core SAD symptoms, and to provide clinical effect sizes, safety, and feasibility data to guide a future definitive efficacy study to establish CBD as a novel evidence based treatment for SAD.
Unavailable. Governed relevance linkage is not ready for this frozen snapshot; no absence of records is inferred.
No matching records in this frozen snapshot.
FAERS package linkage is unavailable; zero reports must not be inferred until exact governed medicine links are ready.
Regulatory records
Registry Results
Registry-submitted primary-outcome values are shown with exact local provenance. The service does not infer efficacy, effect direction or a treatment recommendation from these unreviewed values.
The registry has not posted a Results section for these records. A protocol does not show whether the intervention worked.No registry Results section is pinned in this frozen report snapshot.
A registration describes what was planned. It does not show whether the intervention worked.
Safety
The linked evidence is source-reported and remains candidate-only. Contraindications and patient-specific guidance are not yet validated.
Latest additions
The articles, studies and medicine records shown here are fixed to one dated snapshot. Their source identifiers and links were checked, but the platform has not turned registry entries into clinical conclusions.
This condition is normalized as D001008 using Medical Subject Headings 2026.
35,062 source identifiers verified · snapshot record c847ddc7823f...Dates are derived from this report's immutable package pins. A failed refresh does not replace the last good report.
Limits
Showing 12 of 13,625 frozen records. Browse the complete set →